西妥昔单抗或化疗联合放疗治疗老年口咽癌患者的成本效益分析。
Cost-effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer.
机构信息
Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA.
University of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine; Baltimore, MD 21201, USA.
出版信息
J Comp Eff Res. 2022 Jun;11(8):595-607. doi: 10.2217/cer-2021-0209. Epub 2022 May 11.
To assess the cost-effectiveness of definitive therapies for nonmetastatic oropharyngeal cancer (OPC). Using the Surveillance, Epidemiology and End Results-Medicare dataset, patients diagnosed between 2000 and 2011 were identified. The cost-effectiveness of chemoradiation (CRT) versus radiotherapy (RT), cetuximab plus RT (cetuximab-RT) versus RT and cetuximab-RT versus CRT were estimated. The incremental cost-effectiveness ratio for CRT compared with RT from 2000 to 2005 was US$56,650 (95% CI: US$4,522-$288,688) per additional year of survival. CRT was dominated by RT from 2006 to 2011. Cetuximab-RT was dominated by RT and CRT. CRT had a favorable value from 2000 to 2005 but was dominated by RT from 2006 to 2011. The value of cetuximab-RT compared with RT/CRT was not favorable with similar/inferior survival and substantial incremental costs.
评估非转移性口咽癌（OPC）确定性治疗的成本效益。使用监测、流行病学和最终结果-医疗保险数据集，确定了 2000 年至 2011 年期间诊断的患者。估计了放化疗（CRT）与放疗（RT）、西妥昔单抗联合 RT（西妥昔单抗-RT）与 RT 以及西妥昔单抗-RT 与 CRT 的成本效益。从 2000 年到 2005 年，与 RT 相比，CRT 的增量成本效益比为每年额外生存的 56650 美元（95%CI：4522 美元-288688 美元）。从 2006 年到 2011 年，CRT 被 RT 主导。西妥昔单抗-RT 被 RT 和 CRT 主导。从 2000 年到 2005 年，CRT 具有有利的价值，但从 2006 年到 2011 年，CRT 被 RT 主导。与 RT/CRT 相比，西妥昔单抗-RT 的价值并不有利，因为其具有相似/较差的生存和大量增量成本。
Zotero 插件